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Background: Posttranslational modifications of beta amyloid (Aβ) have been shown to affect its biophysical and
neurophysiological properties. One of these modifications is N-terminal pyroglutamate (pE) formation. Enzymatic
glutaminyl cyclase (QC) activity catalyzes cyclization of truncated Aβ(3-x), generating pE3-Aβ. Compared to
unmodified Aβ, pE3-Aβ is more hydrophobic and neurotoxic. In addition, it accelerates aggregation of other Aβ
species. To directly investigate pE3-Aβ formation and toxicity in vivo, transgenic (tg) ETNA (E at the truncated N-
terminus of Aβ) mice expressing truncated human Aβ(3–42) were generated and comprehensively characterized. To
further investigate the role of QC in pE3-Aβ formation in vivo, ETNA mice were intercrossed with tg mice
overexpressing human QC (hQC) to generate double tg ETNA-hQC mice.
Results: Expression of truncated Aβ(3–42) was detected mainly in the lateral striatum of ETNA mice, leading to
progressive accumulation of pE3-Aβ. This ultimately resulted in astrocytosis, loss of DARPP-32 immunoreactivity, and
neuronal loss at the sites of pE3-Aβ formation. Neuropathology in ETNA mice was associated with behavioral
alterations. In particular, hyperactivity and impaired acoustic sensorimotor gating were detected. Double tg ETNA-
hQC mice showed similar Aβ levels and expression sites, while pE3-Aβ were significantly increased, entailing
increased astrocytosis and neuronal loss.
Conclusions: ETNA and ETNA-hQC mice represent novel mouse models for QC-mediated toxicity of truncated and
pE-modified Aβ. Due to their significant striatal neurodegeneration these mice can also be used for analysis of
striatal regulation of basal locomotor activity and sensorimotor gating, and possibly for DARPP-32-dependent
neurophysiology and neuropathology. The spatio-temporal correlation of pE3-Aβ and neuropathology strongly
argues for an important role of this Aβ species in neurodegenerative processes in these models.
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The formation of pyroglutamate (pGlu, pE) at the N-
terminus of various peptides and proteins is catalyzed
by glutaminyl cyclase (QC, QPCT) and its isoenzyme
(isoQC, QPCTL). Alternatively, glutamine (Q) tends to
form pGlu spontaneously under mild conditions at sig-
nificant rates, which contrasts with glutamate (E) [1-3].
Likewise, glutaminyl peptides are preferred substrates
for both QC and isoQC.
Pyroglutamate decreases solubility of beta amyloid (Aβ),
prevents further enzymatic degradation, and increases sta-
bility [4,5] which may intensify the toxicity of several key
proteins in a number of neurodegenerative diseases.
At present there are several hypotheses for posttrans-
lationally modified proteins accounting for neuropathology
in Parkinson’s disease and Huntington’s disease (HD) [6] as
well as experimental evidence in familial British and
Danish dementia [7-10] and Alzheimer’s disease (AD) [11].
In case of AD, Aβ is generated in the amyloidogenic
pathway, a multi-step cleavage process of the amyloid
precursor protein (APP) [12,13] and pyroglutamate Aβ
(pE3-Aβ) is formed enzymatically during posttransla-
tional peptide maturation via cyclization of N-terminal
glutamate residues of truncated Aβ(3-×) species by QC-
like enzymatic activity [2,14]. The characteristic proper-
ties of pE3-Aβ, high aggregation propensity and stability,
as well as a strong tendency to seed further aggregation
of other Aβ species [9,15,16], result in an Aβ form with
increased toxicity.
Recently, QC-dependent formation of small amounts
of pE3-Aβ inducing decreased synaptic plasticity, pro-
gressive neuronal loss and astrocytosis resulting in an
early neurodegenerative phenotype, has been demon-
strated [17].
The TBA2.1 mouse line described by Alexandru et al.
and other lines, namely TBA2 [18] and FAD42 [19] use
truncated Aβ constructs with an E to Q substitution at
position 3 of the Aβ peptide. The N-terminal Q residue
of the used Aβ(Q3-42) construct is the preferred sub-
strate for QC, but it shows a higher rate of spontaneous
cyclization, compared to the endogenous Aβ species
with E at position 3 [2,3].
In line with this research, several new transgenic (tg)
ETNA (E at the truncated N-terminus of Aβ) mouse
models were generated using a truncated, but non-
mutated and therefore more physiological Aβ(E3-42)
construct to analyze endogenous Aβ(pE3-42) formation
in vivo.
ETNA mice were intercrossed with tg mice over-
expressing human QC (hQC) to further investigate the role
of QC in pE3-Aβ formation in vivo. Interestingly, these
newly generated mouse lines show significant neuronal loss
in striatum, substantiating the hypothesis of modified Aβ
as crucial molecular player in neurodegeneration.Methods
Experimental animals
Tg ETNA mice were generated by chromosomal integra-
tion of an expression cassette as described for TBA2.1
and TBA2.2 [17]. In brief, murine Thy1.2 regulatory se-
quences flank the coding sequence for a fusion protein
consisting of the pre-pro peptide of murine thyrotropin-
releasing hormone (TRH, Thyroliberin) fused to the N-
terminus of the truncated human Aβ(3–42) and directs
expression into neuronal tissue [20]. The regulatory ele-
ments prohormone convertase (PC) cleavage within the
trans-Golgi and secretory vesicles liberates Aβ(3–42)
preferentially within the secretory pathway, where they
are modified by QC activity [21,22].
Similarly, tg hQC mice were generated by integration
of a Thy1.2 expression cassette containing the coding
sequence of hQC (NM_012413) into the chromosome of
CBA/C57BL/6 hybrid embryos. F1 tg animals which
yielded strong genomic southern blot hybridization sig-
nals, using labeled expression cassette probes, were se-
lected for colony expansion and backcrossed to C57BL/6
wildtype (wt) animals. Transgene expression levels in the
established colonies were characterized by real-time
quantitative reverse transcription PCR (qRT-PCR). The
mouse lines E5, E8, and hQC displayed high transgene
transcription rates and were selected for phenotypic
analysis.
The following genotypes of tg and control animals
were used (Table 1). Heterozygous (het) and homozy-
gous (hom) E5 were compared to wt littermates. E8 het
and E8 hom were compared to wt littermates. By inter-
crossing E5 and E8, double heterozygous E85 het/het
were generated and compared to wt/wt littermates.
E8 and E85 were intercrossed with hQC to generate
multi-tg E8-hQC and E85-hQC. In the genotype descrip-
tion of multi-tg ETNA-hQC animals, the hQC allele is
always indicated last. E8-hQC hom/wt, hom/het, and
hom/hom were compared to wt/wt littermates. E85-
hQC always refers to het/het for the E85 alleles and both
wt and hom of the hQC allele were used. As no gender
differences were observed in these lines, both male and
female animals were used in this study. For all experi-
ments, mice of the age 1 to 14 months were used, while
the maximum age difference in one group was 7 days.
Animal care
Laboratory animal care and experiments were conducted
in accordance with the German animal protection act
and the regulations of the government of Upper Bavaria
(Regierung Oberbayern; permission TVA 55.2-1-54-2531-
135-07). In this proposal the role of the enzyme QC in the
development of AD should be investigated. Thereby the
question should be addressed, if a genetic modulation of
Aβ or a pharmacological inhibition of QC-activity can
Table 1 Genotypes of transgenic animals
ETNA nomenclature E8 E5 hQC
E5 wt - wt -
E5 het - het -
E5 hom - hom -
E8 wt wt - -
E8 het het - -
E8 hom hom - -
E85 wt/wt wt wt -
E85 het/het het het -
E8-hQC wt/wt wt - wt
E8-hQC hom/wt hom - wt
E8-hQC hom/het hom - het
E8-hQC hom/hom hom - hom
E85-hQC het/het/wt het het wt
E85-hQC het/het/hom het het hom
Overview of used genotypes and nomenclature of ETNA models. Wildtype
(wt), heterozygous (het), and homozygous (hom) animals of single transgenic
E5 and E8 models were used.
For the double transgenic E85 model, the E8 and E5 models were crossbred
and only double heterozygous (het/het) and wildtype (wt/wt) animals
were used.
E8 and E85 animals were intercrossed with hQC animals to generate multi-tg
ETNA-hQC animals. In these models the genotype of the hQC allele is always
indicated last.
For the double transgenic E8-hQC model, In E8-hQC the E8 allele was always
homozygous in hom/wt, hom/het, and hom/hom animals and wildtype (wt/
wt) animals were used as control.
For the triple transgenic E85-hQC model the E8 and E5 alleles were always
double heterozygous (het/het) and wt, and hom of the hQC allele was used.
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designed to minimize any pain and stress experienced by
the animals. Prior to the study, the number of required
animals was statistically determined and not exceeded
during the experiments. Number of animals and all animal
protocols were specifically approved by the governmental
animal ethics committee of Upper Bavaria. Health and im-
mune status of all experimental animals was constantly
monitored.
Animal housing and husbandry
All mice were maintained in individually ventilated cages
(IVC; Tecniplast, cage Euro-standard Type II L) animal
units in a temperature (22 +/−2°C) and humidity (55 +/−
10%) controlled facility with a 12 h light/dark cycle (lights
on at 6 a.m.), using standard sterile bedding and had ac-
cess to standard laboratory pellets (ssniff Spzialdiät) and
water ad libitum.
Preparation of brain tissue
Mice were transferred to the preparation laboratory,
deeply anesthetized with carbon dioxide, and trans-
cardially perfused with phosphate-buffered saline (PBS).
Brains were removed from the skull and sagitallybisected. Both hemispheres were used for different
analyses to reduce the number of used animals and
to correlate neurodegeneration and protein levels per
animal. Left hemispheres were snap-frozen in liquid
nitrogen and stored at −80°C for analysis of enzyme ac-
tivity, mRNA or protein levels. Right hemispheres were
cut into sample pieces and immersion-fixed in IHC Zinc
Fixative (BD Pharmingen) according to the manufac-
turer’s protocol.
Genetic characterization of transgenic models
Mapping of the chromosomal transgene integration sites
for ETNA and hQC lines was performed as described
before [23] using the Genome Walker Universal Kit
(Clontech). ETNA transgene expression levels were
assessed by qRT-PCR. In brief, brain biopsies were ho-
mogenized in QIAzol reagent (Qiagen) using an Ultra
Turrax disperser (Sigma) and, after centrifugation, total
RNA was further purified from the aqueous phase using
RNeasy spin columns (Qiagen). 1 μg RNA was reverse
transcribed using oligodT primers and Superscript II
(Invitrogen) according to manufacturer’s instructions.
PCR reactions were performed in duplicates using 1 μl
of resulting cDNA per 20 μl reaction volume containing
QuantiTect SYBR Green PCR Master Mix (Qiagen). The
housekeeping gene beta-actin (ACTB) was used as con-
trol. Two ETNA transgene-specific primer sets were
used for PCR amplification with one set containing pri-
mer pairs 5′-AAACGCCAATTCCGACAT-3′ (forward)
and 5′-GAAGGACCTCGAGTTACGC-3′ (reverse), and
the other set containing primers 5′-CTCTTGGCAC
CTAGAGGATCT-3′ (forward) and 5′-AAGGTCAGGA
GTCACAGCAC-3′ (reverse). Primers for amplification
of the human QC transcript were 5′-ACCCTCAAT
CCCACTGCTAA-3′ (forward) and 5′-CTGGCTTGGA
GTCTGAAACA-3′ (reverse). Primers for mouse ACTB
were purchased from Qiagen. PCR was performed on a
LightCycler instrument (Roche) according to preset
protocol and mRNA levels were analyzed by the ΔΔCt
method.
ELISA analysis of total Aβ and pE3-Aβ protein levels
Hemisected brains were homogenized in 2.5 ml of TBS
by means of a Precellys homogenizer (Peqlab) followed
by sonication for 3 × 10 s. The resulting homogenate
was centrifuged at 75,000 × g for 1 h at 4°C. The super-
natant was stored at −80°C and Aβ peptides were further
extracted with 1 ml of 70% formic acid (FA). The solu-
tion was neutralized by addition of a Tris base solution
(3.5 M) and further diluted by 6.05 ml of ELISA blocker
solution (Pierce). The TBS and FA fractions were
subjected to Aβ(×-42) and Aβ(pE3-42) ELISA (IBL Inter-
national). ELISA analysis was performed according to the
manufacturer’s instructions. Following quantification, the
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ized to the brain wet weight.
Enzyme activity analysis of QCs
QC/isoQC activity was determined using a discontinu-
ous assay, which is based on HPLC-UV. Tissue samples
were homogenized in a buffer consisting of 10 mM Tris,
100 mM NaCl, 5 mM EDTA, 0.5% Triton X-100 and
10% Glycerol, pH 7.5, using a Precellys homogenizer
(Peqlab). Reaction samples consisted of 50 μM Q-βNA
in 25 mM MOPS, pH 7.0, 0.1 mM N-ethylmaleinimide
and enzyme solution in a final volume of 1 ml. The reac-
tion temperature was 37°C. Test samples were removed
for up to 1 h, and the reaction was stopped by boiling
for 5 min. The supernatant was applied to HPLC analyses
on a RP18 LiChroCART HPLC Cartridge. The substrate
Q-βNA and the pE-βNA were separated by increasing
concentration of acetonitrile in water containing 0.1%
TFA. The concentration of pE-βNA was determined from
a standard curve determined under assay conditions.
Primary screening of general health and behavior
Semi-quantitative characterization of general health,
neurological reflexes and sensory functions was achieved
by monthly application of a battery of assays generally
referred to as the SHIRPA screening protocol [24]. These
consistied in primary screening of muscle and lower
motor neuron functions, spinocerebellar, sensory, neuro-
psychiatric, and autonomic functions. Primary screening
provides a behavioral and functional profile by observa-
tional assessment, suitable for detecting phenotypes that
could interfere with further behavioral assays. Highly
standardized primary screens were applied by trained ob-
servers blinded to the genotype of the animals and were
initiated with observing social behavior in the home cage
(home cage observation) subsequently followed by moni-
toring of undisturbed behavior of single animals in a clear
plexiglass arena for 90 s (individual observation). This
analysis was followed by a battery of simple behavioral as-
says characterizing the acoustic startle reflex, hanging be-
havior, visual placing, falling behavior, righting reflex,
postural reflex, negative geotaxis, hanging wire, ear twitch,
whiskers twitch, and eye blink, as well as assessment of
dysmorphology and body weight [25].
Automated phenotyping analysis of locomotor activity
Circadian patterns of locomotor activity were assessed
using the PhenoMaster system (TSE Systems). Two
horizontally staked infrared-sensor frames detected loco-
motion in the horizontal axis, and rearing events in the
vertical axis. Continuous recording of these parameters
was carried out simultaneously for all mice in individual
observation units (standard type III cages with grid lid)
for 136 h or 44 h, starting at 2 p.m. Data was collectedautomatically with a rate of 100 Hz and stored on a
personal computer as a sum over 1 min intervals. The
observations took place under a 12-h light/dark-cycle
(lights on at 6 a.m.; lights out at 6 p.m.). Animals re-
ceived water and food ad libitum and remained undis-
turbed by the investigator during observation.Acoustic startle response and prepulse inhibition
The experimenter was blinded to the genotype of the
animals. Female E85 mice were placed in random order
in a startle chamber (TSE Systems) and habituated for
30 s with 68 dB white noise. 10 baseline startle trials with
120 dB white noise were conducted and reactivity was
measured in changes of pressure on the floor plate. Base-
line determination was followed by prepulse inhibition
(PPI) test consisting of 62 randomized trials (10 startle tri-
als: 20 ms of 120 dB white noise; 4 × 10 prepulse + startle
trials: 20 ms of white noise preceded 100 ms by 20 ms of
72 dB, 76 dB, 80 dB, or 84 dB white noise; 4 × 3 control
trials: 20 ms of 72 dB, 76 dB, 80 dB, or 84 dB white noise
followed by 100 ms of 68 dB white noise).Immunohistochemical studies
Immersion-fixed brains were dehydrated, embedded in
low-melting-point paraffin (DCS Innovative Diagnostic
Systems) and sectioned at 8 μm on a rotating microtome.
After deparaffinization, sections were incubated with the
primary antisera overnight at 4°C. For immunodetection,
a biotinylated species-specific IgG secondary antibody
was used, followed by signal enhancement with an
avidin-biotin-complex (Vectastain ABC Kit; PK-6100;
Vector Laboratories) and visualized by peroxidase re-
activity (ImmPACT Peroxidase Kit; SK-4105; Vector
Laboratories).
In double fluorescent immunolabeling procedures, sec-
ondary antibodies were Cy-2- or Cy-3-coupled species-
specific IgGs.
In this study Aβ-specific antibody 6E10 (mouse monoclo-
nal; SIG-39320; Covance; 1:10,000 dilution), pE3-Aβ-spe-
cific antibodies Abeta-pE3 (rabbit polyclonal; 218003;
Synaptic Systems; 1:100,000 dilution) and Abeta-pE3
(mouse monoclonal; 218011; Synaptic Systems; 1:10,000
dilution), QC-specific antibody 1302 (rabbit polyclonal;
Probiodrug; 1:1,000 dilution), and human QC-specific
antibody 8696 (rabbit polyclonal, Probiodrug; 1:1,000
dilution), glia-specific antibody GFAP (rabbit polyclonal,
Z0334; DAKOCytomation; 1:30,000 dilution), activated
caspase 3-specific antibody (rabbit polyclonal, 9661, Cell
Signaling Technology; dilution 1:100), neuron-specific
antibody NeuN (mouse monoclonal; MAB377; Chemicon-
Millipore; 1:10,000 dilution), and DARPP32-specific anti-
body (rabbit monoclonal; 1710–1; Epitomics; 1:10,000
dilution) were used as primary antibodies.
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IgG (M.O.M. Kit; BMK-2202; Vector Laboratories; 1:500
dilution), biotinylated rabbit-specific IgG (goat, Vector
Laboratories; 1:500 dilution), Cy-2-coupled rabbit-specific
IgG (goat, Dianova; 1:250 dilution), Cy-3-coupled rabbit-
specific IgG (goat, Dianova; 1:250 dilution), Cy-2-coupled
mouse-specific IgG (goat, Dianova; 1:250 dilution), and
Cy-3-coupled mouse-specific IgG (goat, Dianova; 1:250 di-
lution) were used.
Semi-automated quantification with CellProfiler
For quantification, 8 μm coronal sections, of the right
hemisphere, corresponding to stereotaxic levels bregma
0.14 mm to 0.38 mm (as defined in Paxinos and Franklin
[26]) were used for analysis. To quantify pE3-Aβ positive
cells, images including all stained striatal cells of pE3-Aβ
stained slides were taken. To quantify neuronal num-
bers, parallel sections were stained with NeuN and a
region of interest (ROI) was defined. Images were taken
with the Picture Frame Application 2.3 (Optronics)
using a Nikon Eclipse 80i microscope (Nikon Instru-
ments) with a MicroFIRE2.3A camera (Optronics).
To count the number of stained cells, CellProfiler (CP)
(r10997) software was used, which enables simultaneous
high throughput measuring of size, shape, intensity and
texture of cells [27]. A detailed protocol, definition of
the ROI, both used ‘pipelines’, and raw data examples are
provided as Appendix 1. Briefly, every image was inverted,
converted from RGB to grayscale and stained cells were
identified by contrast, shape, and size.
Results
Transgenic integration
Several tg mouse lines were generated and examined
alone or in intercrosses in order to characterize QC-
dependent pE3-Aβ formation and neurotoxicity in vivo.
The expression cassettes of ETNA lines consist of the
pre-pro-sequence of murine TRH fused to the coding
sequence of human Aβ(3–42) (Figure 1A). Processing of
the TRH sequence in the secretory pathway of neurons
is facilitated by signal peptidases and PCs [28] leading to
the preferential liberation of Aβ(3–42) within the trans-
Golgi network and secretory granules. Two independent
tg lines (E5 and E8) were established to examine trans-
gene dosage effects. By intercrossing both lines, double
het/het animals were generated. These animals were
termed E85 and examined in order to minimize data mis-
interpretation due to positional effects based on chromo-
somal transgene insertion.
In transgene integration mapping experiments for line
E8, the 5′ flanking region of the expression cassette was
identified as part of a DNA repeat element, presumably
on chromosome 6. This element is repeated eight times
and therefore the exact localization of the expressioncassette remains unknown. Attempts to isolate the 3′-
flanking regions were not successful.
In line E5, the transgene cassette has integrated as
multimer in a head-to-head orientation. The mapping
experiments did not deliver any flanking chromosomal
regions. However, the head-to-head orientation of the
cassette allows differentiation of the E5 and E8 tg alleles
in PCR-based genotyping assays.
Mapping experiments for mouse line hQC demon-
strated that a 3′- integration of the expression cassette
occurred on chromosome 13 (map position 89.0 Mbp;
NCBI Build 36) in intron 1 of the mouse Edil3 gene
(EGF-like repeats and discoidin I-like domains 3). PCR
reactions on homozygote DNA with primer sets binding
to regions upstream of the integration site showed that
the integration event deleted a DNA region of about
50 kb. Hence, integration of the expression cassette re-
moved the first coding exon of Edil3 and hom animals
are devoid of Edil3 gene function.
Construct expression and processing
Transgene expression was quantified using qRT-PCR
analysis in those lines originating from the carefully
selected founder lines. E5 and E8 show similar mRNA
levels, with E5 expressing about 90% of the transgene
compared to E8 (data not shown).
ELISA analysis of protein levels revealed substantial
amounts of total Aβ in E5, E85, and E8. At both 1 and
9 months of age, highest levels were detected in E8 and
lowest in E5, while levels in E85 were intermediate
(Figure 1B). Total Aβ levels detected by ELISA include all
forms endogenic Aβ, the truncated Aβ(3–42) construct,
unprocessed mTRH prepro-Aβ(3–42), and also any par-
tially processed precursor molecules. Concentrations up to
2.5 mg/g were detected in the brains of hom E8, although
the exact amount of present Aβ could not be determined.
Showing distinct pyroglutamyl modification of the N-
terminally truncated Aβ(3–42) peptide, significant levels
of pE3-Aβ were detected in all 3 lines. At the age of
9 months these pE3-Aβ levels reflected a similar distri-
bution pattern among genotypes as detected for total Aβ
levels (Figure 1C).
General health and behavioral phenotype
Monitoring of general health revealed an average litter
size of all ETNA mouse lines (E5, E8, and E85) in
accordance with the expectation from a C56BL/6 inbred
background. Analysis of genotypes revealed a nearly
Mendelian ratio of homozygous (hom), het, and wt ge-
notypes (data not shown).
Analysis of survival revealed no significant differences
between genotype groups for hom E8 (Figure 2A) and het/
het E85 (Figure 2B) mice until the age of 10 months, but
showed a trend for higher mortality in both E8 and E85.
Figure 1 Construct expression and processing. In the construct of ETNA Aβ(3–42) is fused to pre-pro-TRH for product liberation within the
secretory pathway. After prohormone convertase cleavage the N-terminally truncated Aβ peptide is transported into the trans-Golgi and secretory
vesicles, where the N-terminus is available to QC for cyclization (A); adapted from Alexandru et al., 2011. Quantification of protein levels by ELISA
of ETNA brains revealed highest total Aβ levels for hom E8, lowest for hom E5 and intermediate for het/het E85 at two different ages (B); total
Aβ values expressed as percentage of hom E8 at the age of 9 months; data represent means ± SEM; n ≥ 5 animals per genotype. These protein
level relations between the three lines are reflected by similar relations of pE3-Aβ levels at the age of 9 months (C); data represent means ± SEM;
n≥ 5 animals per genotype.
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ences between hom E8 (Figure 2C) or het/het E85
(Figure 2D) mice and wt littermates, respectively.
Monthly monitoring of general health, neurological re-
flexes and sensory functions in the primary screening
showed no obvious alterations, with the exception of the
acoustic startle reflex (see section acoustic reactivity and
sensorimotor gating).
Various tests for basal physiological responses as well
as in-depth characterization of emotionality, cognition,and pain perception revealed no significant differences
(data not shown).Locomotor activity
To analyze the circadian pattern of various behavioral
parameters, ETNA mice were monitored using the auto-
mated PhenoMaster system. In this system, food and
water consumption, as well as locomotor and rearing ac-
tivity were recorded. None of the tested animals showed
Figure 2 General health. Monitoring of survival rates up to the age of 10 months revealed no significant differences between hom E8 (A) or
het/het E85 mice (B) compared to wt animals, respectively; dots represent dead or censored animals; data were analyzed by logrank test of
survival curves; p > 0.05; n ≥ 50 animals per group. Monitoring of bodyweight revealed a moderate, but not significantly reduced gain of weight
for hom E8 (C); data of each gender were analyzed by two-way ANOVA for repeated measurements followed by Bonferroni’s post hoc test (factor
genotype, n.s. p > 0.05) and represent means ± SEM; n = 4–10 animals per group. A similar reduction of weight gain was observed in het/het E85
(D) compared to wt animals; data of each gender were analyzed separately by two-way ANOVA for repeated measurements followed by
Bonferroni’s post hoc test (factor genotype, n.s. p > 0.05) and represent means ± SEM; n = 10–16 animals per group.
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not shown).
In hom E8 mice aged 10 months, measurement of
total distance moved within 136 h showed significantly
increased locomotor activity compared to wt littermates
(Figure 3A).
For a more detailed analysis, the locomotor activity of
het/het E85 mice was regularly monitored. Beginning
with an age of 4 months het/het E85 mice showed pro-
gressive hyperactivity alterations (data not shown). This
elevated activity is significantly increased starting at the
age of 6 months in het/het E85 mice (Figure 3B). At the
age of 8 months the significant increase in total distance
moved of het/het E85 animals is detectable after only
44 h of recording (Figure 3C).Acoustic reactivity and sensorimotor gating
Monitoring of E8 mice in the primary screening revealed
an impaired reaction to a given acoustic signal beginning
at the age of 2 months affecting 90% of hom E8 animals
at the age of 6 months (Figure 3D).
For a more detailed analysis het/het E85 mice were
monitored monthly at the age of 2 to 10 months in the
primary screening, which showed significantly increased
percentages of affected animals compared to wt litter-
mates (paired t-test of 9 time points, ** p = 0.007, n ≥ 22
animals per genotype).
Importantly, 50% of wt C57BL/6 mice showed reduced
reactivity at the age of 10 months. This is attributable to
an age-related hearing loss mutation in the Cdh23ahl
gene [29,30]. Nonetheless, more than 90% of het/het
Figure 3 Behavioral phenotype. Automated recording of locomotion increased activity of hom E8 animals at the age of 10 months (A); gray
bars indicate dark phases; dots show circadian pattern of cumulative distance moved; data were analyzed by two-way ANOVA for repeated
measurements followed by Bonferroni’s post hoc test (factor genotype, * p = 0.032) and represent means ± SEM; n≥ 4 animals per genotype. This
hyperactivity was confirmed in het/het E85 mice at the age of 6 months (B); data were analyzed by two-way ANOVA for repeated measurements
followed by Bonferroni’s post hoc test (factor genotype, * p = 0.012) and represent means ± SEM; n = 12 animals per genotype. At the age of
8 months in het/het E85 mice, the significantly increased activity is already detectable after 44 h of measurement (C); data were analyzed by two-
way ANOVA for repeated measurements followed by Bonferroni’s post hoc test (factor genotype, * p = 0.017) and represent means ± SEM; n ≥ 10
animals per genotype. Monthly primary screening revealed a progressive decrease of reactivity on a given acoustic signal, affecting ~90% hom E8
animals at the age of 6 months (D); bars show percentage of affected animals; n≥ 7 animals per genotype; only males were used. In het/het E85
animals this behavioral phenotype was delayed, affecting ~90% at the age of 10 months (E); bars show percentage of affected animals; n≥ 22
animals per genotype. Analysis of het/het E85 animals at the age of 7 months, revealed a decrease of PPI of the auditory startle reflex across
72–84 dB prepulse intensity (F); data were analyzed by two-way repeated-measures ANOVA followed by Bonferroni’s post-hoc test and represent
means ± SEM; *** p < 0.001 n = 9–10 animals per genotype.
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http://www.biomedcentral.com/1471-2202/14/108E85 animals were affected, arguing for impaired sensori-
motor gating in these animals (Figure 3E).
To address the cause of reduced acoustic reactivity,
PPI of het/het E85 mice was analyzed. The significant
loss of PPI compared to wt animals indicates impaired
sensorimotor gating (Figure 3F).
Expression of the transgenic product Aβ(3–42)
To identify the expression pattern of the tg product
Aβ(3–42), coronal E5 and E8 brain sections from differ-
ent brain regions and at different ages were stained with
the anti-Aβ antibody 6E10. This histopathological ana-
lysis revealed an early expression of the construct in dif-
ferent brain regions, with most prominent expression in
the striatum.
High immunoreactivity was also detected in amygdala
(Additional file 1: Figure S1B) and single 6E10 positive cells
were found in cortex and brainstem (Additional file 1:Figure 4 Striatal (co-)localizations of Aβ, pE3-Aβ, QC and astroglia in
and pE3-Aβ (green) revealed intraneuronal colocalization of tg product and
immunofluorescent labeling of the lateral striatum showed mQC-specific im
E8 animals (B). Double immunofluorescent labeling revealed increased GFA
positive cells (red) in the lateral striatum of hom E8 animals (C).Figure S1D, E) up to the age of 9 months in ETNA
animals.
In all ETNA lines, the striatal 6E10 signal is intra-
neuronally colocalized with pE3-Aβ reactivity (Figure 4A).
6E10 reactivity was observed in the pyramidal cell layer
of the hippocampus of ETNA mice Additional file 1:
Figure S1C) but up to the age of 9 months (latest time
point of analysis) no pE3-Aβ formation was found (data
not shown).
Double immunofluorescent labeling of striatal sections
revealed mouse QC (mQC)-specific immunoreactivity in
pE3-Aβ positive cells, suggesting QC-dependent pE3-Aβ
formation (Figure 4B).
To further analyze neuropathology, GFAP staining was
performed and revealed activated astroglia in the vicinity
of pE3-Aβ positive neurons, indicating neuroinflammatory
processes in the lateral striatum of ETNA animals
(Figure 4C).lateral striatum. Double immunofluorescent labeling of total Aβ (red)
pE-modified Aβ in the lateral striatum of hom E8 animals (A). Double
munoreactivity (red), which is colocalized with pE3-Aβ (green) in hom
P reactivity (green) of activated astroglia in the vicinity of pE3-Aβ
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To analyze the kinetics of neuropathology, protein levels
were quantified by ELISA and the striatum of E5, E85,
and E8 mice were stained with markers for Aβ species,
neuroinflammation, neurodegeneration, and dopamine-
and cAMP-regulated phosphoprotein of 32 kDa (DARPP-
32) across age. In hom E8 animals, progressive pE3-Aβ
formation and neurodegenerative processes are observed
from the age of 3 months, while E5 and E85 mice show
delayed kinetics (data not shown).
Brains of hom E8 animals were analyzed in more detail
at the age of 1, 3, 6, 9, and 12 months and compared to
wt animals (Figure 5).
Expression of the Aβ construct in the striatum can
already be visualized starting at the age of 1 month with
increasing signal up to 9 months (Figure 5A), whilst
pE3-Aβ is detected from 3 months of age (Figure 5B).
Quantification of pE3-Aβ positive cells revealed an expo-
nential increase from 3 to 9 months (Figure 5G).
Staining with GFAP revealed activated astroglia in re-
gional and temporal correlation of pE3-Aβ positive cells
until the age of 9 months, while at 12 months the whole
striatum shows extensive neuroinflammation (Figure 5C).
Activated caspase 3 signal progressing from the age of
3 months suggests pE3-Aβ-associated apoptotic processes
in the lateral striatum of hom E8 animals (Figure 5D).
Progressive decrease of DARPP-32 reactivity of neuro-
pil in the same region was detected starting at the age of
6 months (Figure 5E), while intraneuronal immunoreac-
tivity seemed to be unaffected (data not shown).
These neurodegenerative processes ultimately resulted
in decreased numbers of NeuN positive cells indicating
striatal cell loss beginning in at the age of 6 months
(Figure 5F).
Quantification of protein levels by ELISA of whole E8
brain hemispheres revealed weak construct expression in
juvenile animals, while from 3 to 12 months total Aβ is
comparatively robust (Figure 5H; white bars).
Levels of pE3-Aβ are detectable from the age of
6 months rising until 9 months (Figure 5H; black bars).
The protein levels are in line with histopathological
analysis of striatum, highlighting the striatum as the re-
gion with the strongest alterations in the ETNA mouse
model.
Reductions of protein levels and immunoreactive cells
of total Aβ and pE3-Aβ at 12 months seem to be caused
by the lack of construct-expressing and pE3-Aβ-forming
neurons in the degenerated striatum of homozygous E8
animals.QC overexpression
To analyze the influence of QC on pE3-Aβ and neuro-
pathology, E8 and E85 animals were intercrossed withmice overexpressing human QC (hQC) generating ETNA-
hQC mice.
Staining of striatal brain sections of E8-hQC animals
with specific hQC antibody confirmed intraneuronal co-
expression of hQC and pE3-Aβ (Figure 6A).
While endogenous QC-activity is constant in aging
ETNA mice and shows the same levels as wt control an-
imals (data not shown), het overexpression of hQC leads
to a ~5 fold increase and hom overexpression to an ~10
fold increase of QC activity in the brains of ETNA ani-
mals (Figure 6B).
ETNA hom and ETNA-hQC hom/wt showed indistin-
guishable total Aβ levels, pE3-Aβ levels, and striatal
neuropathology confirming that the genetic background
of hQC wt animals had no influence on pE3-Aβ forma-
tion or neurodegeneration (data not shown).Influence of hQC overexpression on pE-Aβ formation
Already at the age of 3 months, enhancing QC activity
in hom E8 animals lead to a gene dosage-dependent in-
crease of striatal pE3-Aβ positive cells (Figure 7A) which
was obvious at 6 months of age (Figure 7B).
As expected, quantification of pE3-Aβ positive cells re-
vealed a significant increase in E8-hQC and E85-hQC
mice (Figure 7C).
Quantification of pE3-Aβ levels by ELISA revealed
similar distribution, but E85-hQC animals showed a
more than 10fold increase of pE3-Aβ protein value com-
pared to E85 mice (Figure 7D).
Overexpression of hQC had no influence on total Aβ
levels detected by ELISA in both ETNA-hQC lines (data
not shown) arguing for QC-dependent pE3-Aβ forma-
tion in the ETNA mouse model.Influence of hQC overexpression on neuropathology
To analyze the influence of hQC overexpression on
neuropathology, double tg E8-hQC mice at the age of
6 months were stained with neurodegenerative and
neuroinflammatory markers and striatal cell loss was
quantified (Figure 8).
Although hom E8 animals showed obvious striatal
neuroinflammation compared to wt animals, GFAP re-
activity seemed to be enhanced by overexpression of
hQC (Figure 8A).
Low DARPP-32 reactivity in striatum of homozygous E8
brain sections was further decreased by overexpression of
hQC (Figure 8B).
Neuron-specific staining with NeuN-antibody of E8-hQC
mice showed hQC dependent decrease of immunoreactivity
(Figure 8C). To further analyze the influence of hQC
overexpression on neurodegeneration, a region of interest
(ROI) was defined in the lateral striatum (Figure 8D) and
neuronal numbers were quantified.
Figure 5 (See legend on next page.)
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Figure 5 Kinetics of homozygous E8 mice. Immunohistochemical analysis of hom E8 animals from the age of 1–12 months compared to wt
animals (A-F). Staining with 6E10 revealed progressive increase of total Aβ immunoreactivity from the age of 1–9 months with a decline at
12 months (A). Increase of pE3-Aβ reactivity from 3–9 months and decline at 12 months (B) is accompanied by GFAP reactivity (C). Apoptotic
processes are indicated provided by progressive caspase 3 activity beginning at the age of 3 months (D). The lateral striatum shows a progressive
decrease of DARPP-32 reactivity of neuropil from the age of 6 months (E). The different processes result in decreased NeuN positive cells of E8
animals indicating cell loss beginning in at the age of 6 months (F). Quantification of pE3-Aβ positive cells in the striatum of hom E8 animals
revealed exponential increase from 3–9 months and declining numbers at the age of 12 months to the level of 6 months (G); data were
analyzed by one-way ANOVA followed by Newman-Keuls post-hoc test and represent means ± SEM; ** p < 0.01; *** p < 0.001; n = 4–8 animals per
group. Quantification of protein levels by ELISA of hom E8 brains revealed an progressing increase of total Aβ until the age of 6 months; pE3-Aβ
protein levels are detectable from the age of 6, reaching its maximum at the age of 9 and declining at 12 months (H); protein values are
expressed as percentage of hom E8 brains at the age of 6 months; data were analyzed by one-way ANOVA followed by Newman-Keuls post-hoc
test and represent means ± SEM; ** p < 0.01; *** p < 0.001; n = 3–9 animals per group; <LOQ (below level of quantification).
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E8-hQC mice revealed a significant increase of neuronal
loss from 21% for hom/wt to 45% for hom/hom com-
pared to wt animals (Figure 8E).
Discussion
Numerous studies support a gain of toxic function of Aβ
due to post-translational modifications such as isoaspartate
formation, nitrosylation [31], and formation of pyro-
glutamate [10,11,30,32]. In order to assess the pathological
consequence of enhanced pE-Aβ in vivo, several tg mouse
models expressing truncated human Aβ with an N-
terminal Q to E substitution have been generated [17-19].
Although these models display differences in terms of be-
havior and neuronal loss, they commonly suggested thatFigure 6 QC overexpression. Double immunofluorescent labeling of hom
(red) colocalized with pE3-Aβ (green) in the striatum (A). Analysis of QC ac
ETNA animals compared to wt animals and a ~60-fold increase for het and
analyzed by one-way ANOVA followed by Newman-Keuls post-hoc test andan increase of pE-Aβ enhances neuronal dysfunction. With
regard to TBA2 and TBA2.1 mouse models, the ETNA
gene product is the same. However, pE3-Aβ formation in
ETNA is not accelerated by an exchange of E by Q at
position 3 of Aβ. As shown in previous studies, the N-
terminal E residues represent worse substrates for QC (and
isoQC) compared to Q, and E residues should not cyclize
spontaneously considering a half-life of 10–40 years
in vivo [2,3]. In accordance with such slower formation
of pE-Aβ(3–42) also in vivo, we observed the behavioral
changes and neuronal loss at a later time point com-
pared to TBA2.1.
Furthermore, in ETNA the tg product, Aβ(3–42), is
mainly expressed in the lateral striatum compared to the
hippocampal and brainstem expression in TBA2.1. In this/hom E8-hQC animals revealed human QC specific immunoreactivity
tivity at the age of 6 months revealed an indistinguishable activity for
~100-fold increase for hom overexpression of hQC (B); data were
represent means ± SEM; *** p < 0.01; n = 2–12 animals per group.
Figure 7 Influence of QC overexpression on pE3-Aβ formation. Staining of striatal sections of transgenic E8-hQC mice demonstrated an
increase of pE3-Aβ positive cells by het and hom hQC overexpression, respectively at the age of 3 months (A) and 6 months (B). Quantification
of these pE3-Aβ positive cells revealed a significant increase for het and hom overexpression of hQC in homs E8 animals at the age of 6 months
and in het/het E85 animals at the age of 7 months (C); E8 were analyzed by one-way ANOVA followed by Newman-Keuls post-hoc test; E85 were
analyzed by unpaired t-test; data represent means ± SEM; * p < 0.05; *** p < 0.001; n = 7–11 animals per group. Quantification of pE3-Aβ levels by
ELISA revealed a significant increase for het and hom overexpression of hQC in hom E8 brains at the age of 6 months and in het/het E85 brains
at the age of 7 months (D); E8 were analyzed by one-way ANOVA followed by Newman-Keuls post-hoc test; E85 were analyzed by unpaired t-
test; data represent means ± SEM; ** p < 0.01; *** p < 0.001; n = 5–11 animals per group.
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pE3-Aβ formation associated with neuroinflammatory,
apoptotic, and neurodegenerative processes, including
but not limited to a reduced DARPP-32 immunoreac-
tivity. The behavioral phenotype of single tg ETNA
mice, hyperactivity and impaired acoustic sensorimotor
gating, is associated with striatum the brain region with
distinct neuropathology.
Key feature of the neuropathological process is a pro-
gressive site-specific expression of pE3-Aβ, which is as-
sociated with increased caspase 3 and GFAP expression,ultimately resulting in significant cell loss of medium-
sized spiny neurons (MSN), the major cell type in the
striatum [33].
Interestingly, TBA2.1 mice have also shown expression
of the Aβ(Q3-42) construct in the striatum and hippocam-
pus. Only in the latter brain region, pE3-Aβ formation and
neurodegeneration is observed in these animals [17]. ETNA
mice, which use the same Thy1.2 promoter and expression
cassette and only differ in one amino acid, express the
Aβ(E3-42) construct in the same regions, but surprisingly
pE3-Aβ formation and neurodegeneration mainly occurs in
Figure 8 Influence of QC overexpression on neuropathology. Immunohistochemical staining of 6 month old double tg E8-hQC mice
revealed hQC dependent increase of GFAP reactivity of activated astroglia in the striatum (A). Staining of 6 month old E8-hQC mice revealed hQC
dependent decrease of DARPP-32 reactivity of striatal neuropil (B). These neuroinflammatory and degenerative processes resulted in hQC
dependent decrease of NeuN positive cells demonstrating striatal cell loss beginning in at the age of 6 months (C). Quantification of neuronal
numbers in a defined region of interest (ROI) in the basolateral striatum (D) of E8-hQC mice revealed a neuronal loss of 21% for hom/wt, 26% for
hom/het, and 45% for hom/hom (E); neuronal numbers expressed as percentage of wt; data were analyzed by one-way ANOVA followed by
Newman-Keuls post-hoc test and represent means ± SEM; * p < 0.05; ** p < 0.01; *** p < 0.001 n = 5–8 animals per genotype.
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neuronal loss is exclusively observed in vicinity of pE3-Aβ,
arguing for pE3-Aβ as the neurotoxic Aβ species.Compared to other unmodified Aβ, pE3-Aβ had been
shown to accelerate accumulation of several Aβ species,
serving as seed of Aβ aggregation [15-17]. Although, the
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phenotype of ETNA animals, the properties of pE3-Aβ
and the spatio-temporal correlation with neuropathology
argue for pE3-Aβ as crucial factor. In summary, the pres-
ence of pE3-Aβ seems to trigger the coaggregation and to
influence the neurotoxic properties of other Aβ species.
Despite for the generation of TBA mice the same
Thy1.2 promoter was used as for ETNA mice, in all
models a different brain region showed the most expres-
sion of the tg construct. In TBA2 the most tg expression
was found in the cerebellum [18], TBA2.1 mainly
expressed Aβ in the hippocampus [17], and ETNA mice
showed most expression in the striatum. The different
insertion sites of the tg construct into the genome might
have led to the regional variation of expression intensity,
but the exact mechanism remains unclear.
Also, the kinetics of pE3-42 deposition and neuropath-
ology implies a crucial role of the modified peptide for
neuronal loss. Already at the age of 1 month (first time
point of analysis), hom E8 show expression of the trun-
cated Aβ(3–42) construct in the lateral striatum and
severe Aβ protein levels of brain homogenates were
detected by ELISA. With 3 months of age Aβ expression
of hom E8 animals is increasing, reaching a plateau at
6 months. At this age, immunohistochemical stainings
then revealed exponential pE3-Aβ formation being associ-
ated with immunoreactivity specific for activated astroglia,
increased caspase 3 activity, decrease of DARPP-32 ex-
pression, and blunted NeuN immunoreactivity, which
altogether describe neuroinflammatory and apoptotic neu-
rodegenerative processes.
In temporal correlation of prominent pE3-Aβ forma-
tion first behavioral alterations were detected in single tg
ETNA animals and at the age of 6 months 90% of hom
E8 animals showed decreased reactivity on a given
acoustic signal. These animals showed obvious neuronal
loss in the lateral striatum at the age of 9 months and
hyperactivity was detected at the age of 10 months.
In het/het E85 animals the same chronology of neuro-
pathology and behavioral phenotype was observed with
a delay of 2–4 months.
Moreover, overexpression of hQC has been described to
enhance pE3-Aβ dependent pathology and behavior in
5XFAD-hQC mice [34]. To further analyze the role of QC
on pE3-Aβ formation and neuropathology, E8 and E85 an-
imals were intercrossed with human QC overexpressing
mice to generate double tg ETNA-hQC mice.
These mice showed elevated pE3-Aβ levels and in-
creased neuropathology compared to single tg ETNA
mice providing evidence for QC-dependent formation
of neurotoxic pE3-Aβ in vivo. Overexpression of hQC
had no influence on total Aβ levels detected by ELISA
in both ETNA-hQC lines (E8-hQC and E85-hQC), but
increased pE3-Aβ levels and numbers of pE3-Aβpositive cells in the lateral striatum. Double tg E8-hQC
animals showed hQC gene dose-dependent increase of
GFAP and decrease of DARPP-32 reactivity in the stri-
atum at 6 months of age. Neuronal numbers were quan-
tified in the basolateral striatum of these animals and
revealed a significantly increased neuronal loss of 45%
for hom/hom E8-hQC animals compared to 21% for
hom/wt E8-hQC animals with hQC wt expression.
Enhanced pE3-Aβ formation and pathology in hQC
overexpressing animals provide direct evidence for a
QC-driven process, limited by the available amount of
QC.
The striatal pathology of ETNA contrasts with other
mouse models such as TBA2.1 or hAPP tg mice [35-37].
In most of these models, hippocampal (and cortical) de-
generation has been observed. ETNA mice display only
weak expression of the construct in the pyramidal cell
layer of the hippocampus (Additional file 1: Figure S1C),
from the age of 3 months and no pE3-Aβ formation is
observed up to the age of 9 months in E5, E8, and E85
animals (data not shown).
In accordance with the striatal neuronal loss, sensori-
motor gating impairments, similar to striatal alterations
in HD, have been observed in ETNA mice [38]. Likewise,
in mice with a genetic deletion of DARPP-32 or with point
mutations in phosphorylation sites of DARPP-32, the ef-
fects of stimulating drugs on sensorimotor gating were
strongly attenuated [39].
Impairment of acoustic sensorimotor gating is associ-
ated with striatal neurodegeneration occurring at the
sites of pE3-Aβ expression and diminished DARPP-32
immunoreactivity.
Similarly, the home cage hyperactivity displayed by
single tg ETNA mice is likely to be a consequence of the
underlying striatal pathology, possibly caused by a loss
of GABAergic inhibitory neurotransmission resulting in
a disinhibition of motor function.
While hyperkinetic movement disorders represent an
important subgroup of neurodegenerative disorders, not
all of those affect the striatum [40]. Among them, HD
shows the highest incidence and has been associated
with disturbed dopaminergic as well as downstream
DARPP-32 neurotransmission [41,42]. A loss of inhibi-
tory GABAergic MSNs represents a key feature of the
disease and is causal for hyperactivity [43]. In addition
to their relevance for pE3-Aβ toxicity in AD, ETNA lines
might model selected aspects of HD.
Conclusions
Taken together, ETNA is a new mouse model for Aβ-
toxicity and neuronal loss, associated by a region specific
behavioral phenotype.
The immunohistological characterization, analysis of
protein levels, and behavioral findings of all ETNA lines
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for induction and progression of striatal neuronal loss.
Therefore, the model might be also of interest for inves-
tigation of the role of striatal factors such as DARPP-32
or others in neuronal degeneration in HD as well as for
testing of neuroprotective strategies targeting striatal
degeneration.
Appendix 1
Construct Expression in ETNA animals
To identify the expression pattern of the tg product
Aβ(3–42), coronal brain sections of E5, E8 and E85 from
different brain regions and at different ages were stained
with the anti-Aβ antibody 6E10. In all lines, highest im-
munoreactivity was found in the striatum (Additional
file 1: Figure S1A). Obvious immunoreactivity was also
detected in amygdala (Additional file 1: Figure S1B) and
single 6E10 positive cells were found in cortex and
brainstem (Additional file 1: Figure S1D, E) up to the
age of 9 months. 6E10 reactivity in the pyramidal cell layer
of the hippocampus of ETNA was observed (Additional
file 1: Figure S1C), but up to the age of 9 months (latest
time point of analysis) no pE3-Aβ formation was found
(data not shown).
Protocol of pE3-Aβ cell and neuronal quantification
For quantification 8 μm coronal sections, of the right
hemisphere, corresponding to stereotaxic levels bregma
0.14 mm to 0.38 mm (as defined in Paxinos and
Franklin, 2008) were used for analysis (n = 3–12 sections
per animal).
Images of pE3-Aβ stained slides were taken at 4 ×
magnification (2.9 mm × 2.2 mm), including all stained
striatal cells (Additional file 2: Figure S2A). To quantify
neuronal numbers, parallel sections were stained with
NeuN (Additional file 2: Figure S2C). To quantify only
striatal cells a ROI was defined (Additional file 2: Figure
S2D). All images were taken with constant exposure
time and color balance with the Picture Frame Applica-
tion 2.3 (Optronics) using a Nikon Eclipse 80i micro-
scope (Nikon Instruments) with a MicroFIRE2.3A
camera (Optronics), were saved as Tagged Image Files
(TIF-24-bit) at a resolution of 213 dpi (1600 px × 1200
px) and analyzed with CP.
Region of interest
To avoid neuronal density variances in the striatum due
to high amount of neuropil in the medial striatum a
rectangular ROI was defined in the basolateral striatum
by using 10 × optical magnification (1.6 mm × 0.87 mm)
with maximal lateral position with maximal possible dis-
tance of the lateral ventricle touching the external cap-
sule (ec) and only including cells of the striatum
(Additional file 2: Figure S2).Pipeline quantification of pE3-Aβ positive cells
Load images: Images at 4 × optical magnification
(2.9 mm × 2.2 mm) including all pE3-Aβ stained cells
of the striatum were loaded.
Image math: Images were inverted. CP usually detects
bright immunofluorescence signals with a dark background.
By inverting immunohistochemical images, CP is able to
distinguish dark objects from unstained background.
Color to grey: Images were converted from RGB to
greyscale. CP uses grayscale pictures.
Identify primary objects: The minimum diameter was
set to 1 pixel, and the maximum diameter was set to 10
pixels. Objects outside the diameter range were ex-
cluded. Cells were identified based on their immunohis-
tochemical signal by the ‘robust background global’
algorithm. The threshold correction factor was set to
1.4. Threshold bounds were set from 0.0-1.0. Clumped
objects were distinguished by staining intensity. Identi-
fied objects were called ‘pE3-Aβ positive cells’.
Export to spreadsheet: After finishing the analysis, data
was exported to *.xls for further statistical processing.
Pipeline quantification of neurons in the basal lateral
striatum
An example of the used pipeline is shown in Additional
file 3: Figure S3A.
Load images: Images at 10 × optical magnification
(1.6 mm × 0.87 mm) of the ROI, including only NeuN
stained cells of the striatum were loaded.
Image math: Images were inverted.
Color to grey: Images were converted from RGB to
greyscale.
Identify primary objects: The minimum diameter was
set to 8 pixels, and the maximum diameter was set to 50
pixels. Objects outside the diameter range were ex-
cluded. Cells were identified based on their immunohis-
tochemical signal by the ‘robust background global’
algorithm. The threshold correction factor was set to
1.1. Threshold bounds were set from 0.3-1.0. Clumped
objects were distinguished by staining intensity. Identi-
fied objects were called ‘neurons’ (Additional file 3:
Figure S3B).
Export to spreadsheet: After finishing the analysis, data
was exported to *.xls for further statistical processing.
Additional files
Additional file 1: Figure S1. Regional construct expression and
processing. Example of coronal section stained with 6E10 of homozygous
ETNA animals at the age of 3 months. Most severe immunoreactivity is
found in the striatum (A). Also amygdala (B) showed strong Aβ
expression and pE3-Aβ formation is observed at later time points. In
hippocampus Aβ positive cells were observed in the pyramidal cell layer
(C), but no pE3-Aβ could be observed up to the age of 9 months. In
cortex (D) and brainstem (E) single positive cells were found.
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Example of ETNA striatal coronal section stained with pE3-Aβ specific
antibody, used to quantify pE3-Aβ positive cells by CP software (A).
Images were taken at 4 x magnification and automatically inverted and
transformed into grayscale (B). CP software detects numbers of stained
cells and staining artifacts were excluded by low staining intensity and
size above 10 pixels. To quantify neuronal numbers of ETNA striatal
coronal sections were stained with NeuN-specific antibody. A ROI was
defined as image at 10 x magnification (1.6 mm x 0.87 mm) in the basal,
lateral striatum with maximal possible distance from lateral ventricle (LV),
touching the external capsule (ec) and only including cells of the
striatum (C). Example of ROI used for neuronal quantification (D).
Additional file 3: Figure S3. Pipelines and image analysis. Pipeline (left)
and ‘identify primary objects’ module (right) used to quantify neuronal
numbers by CP software (A). Example of neuronal identification and
segmentation of clumped cells (B). After inversion and transformation
(right upper image), CP detects cells and segments clumped objects by
staining intensity (green, right lower image).Competing interests
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